DDLS Week 4 · Seminar 4 · 01 / 06

Can this KRAS model support residue-level design?

The owner wanted five residues that could guide design of a KRAS inhibitor series. The starting model looked confident, but I needed to determine whether it actually supported that residue-level decision.

Dr Yuki Tanaka · medicinal chemistry KRAS G12D assay construct
02 / What I built

I turned an interview into a testable brief.

The workflow separated three questions: what protein is this, how confident is the local model, and what can I honestly claim?

Owner interviewdesign decision
→
BriefAGENTS.md / spec.md
→
Identity checksequence + boundaries
→
Confidenceper-residue pLDDT
→
Answerfive anchors

Claim

Reliable local shape in the pocket neighbourhood.

Model

Construct-matched KRAS G12D 1–169 fold.

Boundary

Model support is not experimental validation.

03 / The right confidence · visual centrepiece

For a local claim, use local confidence.

The main evidence is per-residue pLDDT in the actual KRAS G12D 1–169 fold — not global pTM.

CHAIN A · B-FACTOR = pLDDT · AUTO-ROTATE

Requested regions

86.94
10–17 mean
min 80.13
68.27
30–38 mean
min 62.00
60.30
57–67 mean
min 45.12

10–17 has the consistently higher local confidence. This is model evidence, not experimental validation.

Full sequence · 1–169

1255075100125150169
■ selected residues · shaded = 10–17
G1087.70
V1489.92
G1590.79
K1687.06
S1787.03
04 / The trap

The confident AlphaFold model was not the exact assay construct.

AlphaFold DB reference

KRAS P01116
G12 · 1–189
canonical reference

Owner's assay construct

KRAS G12D
D12 · 1–169
one chain · no tag
G12 / G12D mismatch
plus the AlphaFold-only C-terminal overhang: residues 170–189

I therefore checked the construct-matched G12D 1–169 structure rather than relying on the canonical model alone. I did not treat the canonical model as sufficient evidence for residue-level contacts in the assay construct.

05 / The answer

Five anchors — one high-confidence local region.

G10 · V14 · G15 · K16 · S17
Model-supported design anchors
Gly1087.70pLDDT
Val1489.92pLDDT
Gly1590.79pLDDT
Lys1687.06pLDDT
Ser1787.03pLDDT
These residues are supported as structural design anchors by the construct-matched model.

Not experimentally validated ligand contacts.

The shortlist supports hypothesis generation and design prioritisation — not proof of binding.

06 / Limitations + AI use

What I can say — and what I still cannot know.

What the model supports

  • Construct-matched KRAS G12D 1–169 fold was checked.
  • Region 10–17 has higher local pLDDT.
  • Five residues can guide design as model-supported anchors.

What it does not establish

  • Experimental ligand contacts.
  • Residue-level mutational validation.
  • The ligand-bound conformational state.

The predicted structure does not establish the ligand-bound conformational state or experimental residue-level contacts.

Next step

Compare an appropriate experimental structure, or use an appropriate complex prediction and evaluate interface/structural confidence.

AI use disclosure
Agent A — owner interview and biological question.
Pi — structural analysis, viewer and presentation draft.
I verified the construct/sequence, residue numbering, pLDDT values, selected residues, structure match and limitations.